Kala Bio (KALA) Other Non-Current Assets (2016 - 2025)
Kala Bio (KALA) posted Other Non-Current Assets of $144000.0 for Q3 2025, down 36.28% sequentially from $226000.0 in Q2 2025, and down 44.62% YoY from $260000.0 in Q3 2024.
Kala Bio (KALA) Other Non-Current Assets (2016 - 2025) Analysis & Trends
Kala Bio has reported Other Non-Current Assets for 10 years, with the latest figure at $144000.0 in Q3 2025.
- Quarterly Other Non-Current Assets fell 44.62% year-over-year to $144000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $144000.0 (down 44.62% YoY) and the FY2024 annual result came in at $246000.0, down 18.27% from the prior year.
- Other Non-Current Assets eased to $144000.0 in Q3 2025 per KALA's latest filing, from $226000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $13.0 million in Q1 2021 and troughed at $144000.0 in Q3 2025.
- A 5-year average of $1.8 million and a median of $328000.0 in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets jumped 419.49% in 2022, then plunged 96.04% in 2023.
- Over 5 years, Other Non-Current Assets stood at $1.5 million in 2021, then surged by 419.49% to $7.6 million in 2022, then slumped by 96.04% to $301000.0 in 2023, then dropped by 18.27% to $246000.0 in 2024, then sank by 41.46% to $144000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $144000.0, $226000.0, and $239000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Kala Bio | 9.89 Mn | 9.89 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 144,000.00 |
| Jun 30, 2025 | 226,000.00 |
| Mar 31, 2025 | 239,000.00 |
| Dec 31, 2024 | 246,000.00 |
| Sep 30, 2024 | 260,000.00 |
| Jun 30, 2024 | 273,000.00 |
| Mar 31, 2024 | 287,000.00 |
| Dec 31, 2023 | 301,000.00 |
| Sep 30, 2023 | 314,000.00 |
| Jun 30, 2023 | 328,000.00 |
| Mar 31, 2023 | 372,000.00 |
| Dec 31, 2022 | 7.60 Mn |
| Sep 30, 2022 | 475,000.00 |
| Jun 30, 2022 | 519,000.00 |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 1.46 Mn |
| Sep 30, 2021 | 3.21 Mn |
| Jun 30, 2021 | 3.22 Mn |
| Mar 31, 2021 | 12.98 Mn |
| Dec 31, 2020 | 12.99 Mn |